Medicines Co
MDCO
MDCO was delisted on the 3rd of January, 2020.
188 hedge funds and large institutions have $3.52B invested in Medicines Co in 2018 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 69 increasing their positions, 62 reducing their positions, and 21 closing their positions.
137% more call options, than puts
Call options by funds: $79.6M | Put options by funds: $33.6M
11% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 62
10% more capital invested
Capital invested by funds: $3.2B → $3.52B (+$321M)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 21
1% less funds holding
Funds holding: 190 → 188 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$17.5M |
| 2 |
LPC
Lion Point Capital
New York
|
+$13.8M |
| 3 |
AH
Aviva Holdings
New Providence,
Bahamas
|
+$13.2M |
| 4 |
JP Morgan Chase
New York
|
+$12.1M |
| 5 |
Citigroup
New York
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$39.4M |
| 2 |
CM
Corvex Management
New York
|
-$36.7M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$21.9M |
| 4 |
TBC
Three Bays Capital
Boston,
Massachusetts
|
-$12.2M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$8.74M |
MDCO Hedge Fund Activity: Q2 2018 in Review
188 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q2 2018, worth a combined $3.52B — up 10% from $3.2B a quarter earlier.
Fund positioning in MDCO was balanced in Q2 2018: 21 funds opened new positions, 21 closed out, 69 added to existing stakes and 62 trimmed.
The largest buyer was BlackRock, adding an estimated $17.5M. The largest seller was Franklin Resources, cutting an estimated $39.4M.
- 188 institutional investors held Medicines Co (MDCO) as of Q2 2018, down from 190 in Q1 2018.
- Funds reported $3.52B of Medicines Co stock for Q2 2018, up 10% quarter-over-quarter.
- 21 funds opened new Medicines Co positions in Q2 2018 and 21 closed out, a net change of 0 holders.
- The largest Medicines Co buyer in Q2 2018 was BlackRock, an estimated $17.5M added.
- The largest Medicines Co seller in Q2 2018 was Franklin Resources, an estimated $39.4M sold.
Based on aggregated 13F filings for Q2 2018.